Dana-Farber Cancer Institute: Potent Oral Agent That Acts as Both Immunotherapy and Targeted Treatment Produces High Response Rate in Patients With Hard-to-Treat and Refractory Multiple Myeloma When Combined With Steroid, Trial Sh
August 31, 2023
August 31, 2023
BOSTON, Massachusetts, Aug. 31 -- The Dana-Farber Cancer Institute issued the following news release on Aug. 30, 2023:
A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies, a clinical trial conducted by researchers at Dana-Farber Cancer Institute and around . . .
A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies, a clinical trial conducted by researchers at Dana-Farber Cancer Institute and around . . .